Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

SONN Sonnet BioTherapeutic

Watchlist
1.480
+0.010+0.68%
Close 10/03 16:00 ET
1.48000.00%
Pre Mkt Price 10/04 06:51 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
1.490
Open
1.480
Turnover
95.21K
Low
1.420
Pre Close
1.470
Volume
65.20K
Market Cap
7.36M
P/E(TTM)
Loss
52wk High
9.618
Shares
4.97M
P/E(Static)
Loss
52wk Low
1.230
Float Cap
7.17M
Bid/Ask %
96.15%
Historical High
1872.780
Shs Float
4.84M
Volume Ratio
0.22
Historical Low
1.230
Dividend TTM
--
Div Yield TTM
--
P/B
9.61
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.35%
Amplitude
4.76%
Avg Price
1.460
Lot Size
1
Float Cap
7.17M
Bid/Ask %
96.15%
Historical High
1872.780
Shs Float
4.84M
Volume Ratio
0.22
Historical Low
1.230
Dividend TTM
--
P/B
9.61
Dividend LFY
--
Turnover Ratio
1.35%
Amplitude
4.76%
Avg Price
1.460
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
CEO: Mohan Ph.D., Pankaj
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top